文献速递脊柱关节炎

比美吉珠单抗双靶向中和IL-17A和IL-17F治疗活动性强直性脊柱炎:48周IIb期随机双盲安慰剂对照剂量探索研究结果

Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study.
PubMed 文献 · Ann Rheum Dis · 2020-04-06

该IIb期研究纳入303例活动性强直性脊柱炎患者,随机分配至比美吉珠单抗16mg、64mg、160mg、320mg或安慰剂组,每4周给药一次。第12周时,比美吉珠单抗组ASAS40应答率显著高于安慰剂组(29.5%-46.7% vs 13.3%,所有比较p<0.05),并观察到显著剂量反应(p<0.001)。第48周时,持续接受160mg和320mg治疗的患者ASAS40应答率分别为58.6%和62.3%,安全性与既往研究一致。

要点

  • 比美吉珠单抗第12周ASAS40应答率显著优于安慰剂,且存在显著剂量反应关系
  • 持续治疗至第48周,160mg和320mg组ASAS40应答率分别达58.6%和62.3%
  • 安全性特征与既往研究一致,未发现预期外不良事件

核心结论

  • 比美吉珠单抗在活动性强直性脊柱炎患者中快速且持续改善关键结局指标,安全性与既往研究一致。

研究设计与样本

  • IIb期随机双盲安慰剂对照剂量探索研究,纳入303例符合修改纽约标准的活动性强直性脊柱炎成人患者。
  • 患者按1:1:1:1:1随机分配至比美吉珠单抗16mg、64mg、160mg、320mg或安慰剂组,每4周给药一次,双盲期12周。
  • 第12周后,16mg、64mg和安慰剂组患者按1:1重新随机分配至160mg或320mg组至第48周,其他患者维持原剂量(剂量盲期)。

主要发现

  • 第12周ASAS40应答率(NRI):比美吉珠单抗组29.5%-46.7%,安慰剂组13.3%,所有比较p<0.05,OR vs 安慰剂2.6-5.5(95%CI 1.0至12.9)。
  • 观察到显著剂量反应(p<0.001),主要终点获所有次要疗效结局支持。
  • 第48周ASAS40应答率(NRI):持续接受160mg和320mg治疗者分别为58.6%和62.3%,重新随机分配患者应答率相似。
  • 双盲期治疗中出现的不良事件:安慰剂组26/60(43.3%),比美吉珠单抗组92/243(37.9%)。

关键数值与推荐

  • 主要终点为第12周ASAS40应答率,缺失数据采用无应答者填补(NRI)。
  • 第12周ASAS40应答率比美吉珠单抗组29.5%-46.7% vs 安慰剂组13.3%,所有比较p<0.05。
  • OR vs 安慰剂2.6-5.5(95%CI 1.0至12.9)。
  • 剂量反应p<0.001。

临床怎么用

  • 比美吉珠单抗双靶向中和IL-17A和IL-17F,可为活动性强直性脊柱炎提供快速且持续的治疗选择。
  • 研究中160mg和320mg剂量至第48周的ASAS40应答率均较高,安全性可接受。

局限性

  • 原文未报告局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Bimekizumab selectively neutralises both interleukin (IL)-17A and IL-17F. We report efficacy and safety in a phase IIb dose-ranging study in patients with active ankylosing spondylitis (AS). METHODS: Adults with AS (fulfilling modified New York criteria) were randomised 1:1:1:1:1 to bimekizumab 16 mg, 64 mg, 160 mg, 320 mg or placebo every 4 weeks for 12 weeks (double-blind period). At week 12, patients receiving bimekizumab 16 mg, 64 mg or placebo were re-randomised 1:1 to bimekizumab 160 mg or 320 mg every 4 weeks to week 48; other patients continued on their initial dose (dose-blind period). The primary end point was Assessment of SpondyloArthritis international Society (ASAS) 40 response at week 12 (non-responder imputation (NRI) for missing data). RESULTS: 303 patients were randomised: bimekizumab 16 mg (n=61), 64 mg (n=61), 160 mg (n=60), 320 mg (n=61) or placebo (n=60). At week 12, significantly more bimekizumab-treated patients achieved ASAS40 vs placebo (NRI: 29.5%-46.7% vs 13.3%; p<0.05 all comparisons; OR vs placebo 2.6-5.5 (95% CI 1.0 to 12.9)). A significant dose-response was observed (p<0.001). The primary end point was supported by all secondary efficacy outcomes. At week 48, 58.6% and 62.3% of patients receiving bimekizumab 160 and 320 mg throughout the study achieved ASAS40, respectively (NRI); similar ASAS40 response rates were observed in re-randomised patients. During the double-blind period, treatment-emergent adverse events occurred in 26/60 (43.3%) patients receiving placebo and 92/243 (37.9%) receiving bimekizumab. CONCLUSIONS: Bimekizumab provided rapid and sustained improvements in key outcome measures in patients with active AS, with no unexpected safety findings versus previous studies. TRIAL REGISTRATION NUMBER: NCT02963506.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. van der Heijde D, Gensler LS, Deodhar A, et al. Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study. Ann Rheum Dis. 2020. PMID: 32253184. doi:10.1136/annrheumdis-2020-216980

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。